Document:

Exhibit
10.2

 

Share
Purchase Agreement

 

THIS
Share Purchase Agreement (this “Agreement”) is made as of this
17th day of December, 2019, by and between, Frelii Inc., a company organized under the laws of the State of Utah with its registered
office at 670 West Shepard Lane, Suite 102 Farmington, UT 84025 (“Buyer”), and Genecor Labs Inc., a company
organized under the laws of Ontario with its registered office at 1 Adelaide St E, Toronto, ON M5C 2V9 (“Seller”).

 

Whereas

 

Whereas,
Seller owns 100 common shares (the “Shares”) in Genecor Labs Inc. (the “Company”), a company organized
under the laws of the Province of Ontario with registered office at 1 Adelaide St E, Toronto, ON M5C 2V9, and

 

Whereas,
Seller wishes to issue to Buyer, and Buyer desires to purchase from Seller common shares representing 25% of the outstanding shares
upon the terms and conditions set forth in this Agreement.

 

Now,
Therefore, in consideration of the mutual covenants
and undertakings contained herein, and subject to the terms and conditions herein set forth, and with the intent to be bound,
the parties to this Agreement (“the Parties”) hereto agree as follows:

 

ARTICLE
I

DEFINITIONS

 

As
used in this Agreement and the schedules hereto, the following terms have the respective meanings set forth below.

 

“Agreement”
shall have the meaning set forth in the Preamble to this Agreement.

 

“Buyer”
shall have the meaning set forth in the Preamble to this Agreement.

 

“Closing”
shall have the meaning set forth in Section 4.1.

 

“Closing
Date” shall have the meaning set forth in Section 4.1.

 

“Company”
shall have the meaning set forth in the Recitals to this Agreement.

 

“Purchase
Price” shall have the meaning set forth in Section 3.1.

 

“Seller”
shall have the meaning set forth in the Preamble to this Agreement.

 

“Shares”
shall have the meaning set forth in the Recitals to this Agreement.

 

    	 	 	 

    	 

    

 

ARTICLE
II

PURCHASE AND SALE

 

2.1
Purchase and Sale of the Shares

 

(a)
Upon the terms and subject to the conditions set forth in this Agreement, at Closing, Seller hereby sells, assigns, transfers,
conveys and delivers to Buyer, and Buyer hereby purchases, acquires and accepts from Seller, free and clear of Encumbrances, the
25% of the right, title and interest in, at the time of Closing, the Shares of the Seller.

 

(b)
Seller hereby irrevocably waives any restrictions on transfer to the extent possible (including any of its rights of pre-emption)
which may exist in relation to the Purchase, whether under the articles of association (or local equivalent) of the Company or
otherwise.

 

ARTICLE
III

PURCHASE PRICE: ALLOCATION OF PURCHASE PRICE

 

3.1
Purchase Price Buyer will exchange shares equal to $752,000 USD (the “Purchase Price”) at $0.20 USD for 25
shares of Genecor Labs Inc.

 

ARTICLE
IV

CLOSING

 

4.1
Closing. Subject to the terms and conditions of this Agreement, the sale and purchase of the Shares contemplated by this
Agreement shall take place at a closing (the “Closing”) held at the offices of 1180 Aerowood Dr, Mississauga,
ON, on the date hereof (the “Closing Date”). Except to the extent expressly set forth in this Agreement to
the contrary, and notwithstanding the actual occurrence of the Closing at any particular time on the Closing Date, the Closing
shall be deemed to occur and be effective as of 12:01 a.m. Toronto time on the Closing Date.

 

4.2
Deliveries at the Closing

 

(a)
Upon the terms and subject to the conditions of this Agreement, at the Closing, Seller shall deliver to Buyer copies of the resolutions
(or local equivalent) of the board of directors (or local equivalent) and, where required, the stockholder(s) of Seller, authorizing
and approving the transactions contemplated by this Agreement, certified by the respective corporate secretary (or local equivalent)
or a director to be true and complete and in full force and effect and unmodified as of the Closing.

 

    	 	2	 

    	 

    

 

(b)
Upon the terms and subject to the conditions of this Agreement, at the Closing, the Buyer shall deliver to Seller copies of the
resolutions (or local equivalent) of the board of directors (or local equivalent) and, where required, the stockholder(s) of Buyer,
authorizing and approving the transactions contemplated by this Agreement, certified by the respective corporate secretary (or
local equivalent) or a director to be true and complete and in full force and effect and unmodified as of the Closing.

 

(c)
Upon the terms and subject to the conditions of this Agreement, at the Closing, the Parties shall sign the transfer of the Shares
of Genecor AI to Frelii Inc. and the Class B Shares of Frelii Inc. to Helix Investments Partners Inc. in the form of warrants
and/or shares in the share register of the respective companies.

 

ARTICLE
V

MISCELLANEOUS

 

5.1 Notices.
Any notice required to be given hereunder shall be sufficient if in writing, and sent by facsimile transmission (provided
that any notice received by facsimile transmission or otherwise at the addressee's location on any business day after 5:00
p.m. (addressee's local time) shall be deemed to have been received at 9:00 a.m. (addressee's local time) on the next
business day), by reliable overnight delivery service (with proof of service), hand delivery or certified or registered mail
(return receipt requested and first-class postage prepaid), addressed as follows:

 

To Buyer:

 

670
West Shepard Lane, Suite 102 Farmington, UT 84025

Attention:
Ian Jenkins, President & CEO

Email:
ianjenkins@frelii.com

 

To
Seller:

 

1
Adelaide St E, Toronto, ON M5C 2V9

Attention:
Tejas Shah, Director

Email:
tshah@genecor.ai

 

    	 	3	 

    	 

    

 

or
to such other address as any Party shall specify by written notice so given, and such notice shall be deemed to have been delivered
as of the date so telecommunicated, personally delivered or mailed. Any Party to this Agreement may notify any other Party of
any changes to the address or any of the other details specified in this paragraph; provided, however, that such
notification shall only be effective on the date specified in such notice or five (5) business days after the notice is given,
whichever is later. Rejection or other refusal to accept or the inability to deliver because of changed address of which no notice
was given shall be deemed to be receipt of the notice as of the date of such rejection, refusal or inability to deliver.

 

5.2
Counterparts: Effectiveness. This Agreement may be executed in two or more consecutive counterparts (including by facsimile),
each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument,
and shall become effective when one or more counterparts have been signed by each of the Parties and delivered (by telecopy or
otherwise) to the other Parties.

 

5.3 Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of Ontario, without giving
effect to any choice or conflict of law provision or rule.

 

5.5
Arbitration. Any dispute, controversy
or claim arising out of or relating to the conclusion, interpretation or performance of the present Agreement, or the breach,
termination or invalidity thereof, shall
be definitively settled by arbitration.

 

The
Parties shall have the arbitration conducted in accordance to the Procedural Rules of Ontario, by an arbitral tribunal appointed
in accordance to the Procedural Rules of Ontario.

 

The
arbitral tribunal shall be composed of three arbitrators.

 

The
place of arbitration shall be Toronto, unless the arbitral tribunal decides otherwise with the agreement of all Parties.

 

The
language of the arbitration shall be the language of the present Agreement, i.e. English.

 

The
Parties hereby waive
their right to any form of recourse against
an award to any court or other competent
authority, insofar as such waiver
can validly be made under the applicable law.

 

5.6
Assignment. No Party to this Agreement may assign any of its rights and obligations
under this Agreement without the prior written consent of the other party hereto; provided, however, either party may assign its
rights and obligations to one or more of its respective Wholly-Owned Subsidiaries (it being understood that such assignment shall
not be permitted if it would delay or impair the consummation of the transactions contemplated hereby); provided, further, that,
no such assignment shall relieve the assigning party of any of its obligations hereunder.

 

5.7
Parties in Interest. This Agreement and
all the provisions hereof shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors
and permitted assigns. This Agreement is for the sole benefit of the parties hereto and their permitted assigns and nothing herein
express or implied shall give or be construed to give to any person, other than the Parties hereto and such permitted assigns,
any legal or equitable rights hereunder.

 

    	 	4	 

    	 

    

 

5.8 Titles
and Headings. The headings and table of contents in this Agreement are for reference purposes only, and shall not in any
way affect the meaning or interpretation of this Agreement.

 

5.9 Entire
Agreement. This Agreement (including the Schedules and Exhibits attached hereto or delivered in connection herewith)
constitutes the entire agreement among the Parties hereto with respect to the matters covered by this Agreement and thereby,
and supersede all previous written, oral or implied understandings among them with respect to such matters.

 

5.10 Further
Action. After Closing, each of the Parties shall do, execute and deliver or procure to be done, executed and
delivered, at the reasonable request and expense of the other Party, all such further acts, deeds, documents, instruments of
conveyance, assignment and transfer and things as may be necessary to give effect to the terms of this Agreement.

 

5.12 Amendment
and Modification. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Parties
hereto.

 

5.13 Waiver.
Any of the terms or conditions of this Agreement may be waived at any time by the party or parties hereto entitled to the
benefit thereof, but only by a writing signed by the Party or Parties waiving such terms or conditions.

 

5.14 Severability.
If any term, provisions, covenant or restriction of this Agreement is held by a court of competent jurisdiction (i.e.
including an arbitral tribunal) or other authority to be invalid, void or unenforceable, the remainder of the terms,
provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be
affected, impaired or invalidated so long as the economic or legal substance of the transactions completed by this Agreement
is not affected in any manner materially adverse to any party. Upon such determination, the parties shall negotiate in good
faith to modify this Agreement so as to affect the original intent of the parties as closely as possible in an acceptable
manner in order that the transactions contemplated by this Agreement be consummated as originally contemplated to the fullest
extent possible.

 

5.15 Interpretation.
(a) Unless otherwise indicated to the contrary in this Agreement by the context or use thereof: (i) the words,
“herein,” “hereto,” “hereof” and words of similar import refer to this Agreement as a
whole and not to any particular Section or paragraph hereof; (ii) words importing the masculine gender shall also include the
feminine and neutral genders, and vice versa; (iii) words importing the singular shall also include the plural, and vice
versa; (iv) the word “including” means “including without limitation”.

 

(b) The Parties have
participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent
arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall
arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement.

 

    	 	5	 

    	 

    

 

5.16 Representations
and Warranties. All representations and warranties in connection with the transfer of the Shares are set forth in
Schedule 1.

 

5.17 Governing
Language. The English language shall be the definitive and controlling text of this Agreement, notwithstanding the
translation of this Agreement into any other language.

 

IN
WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed as of the day and year first above written.

 

	 		 
	Name:	 	 
	Title:	 	 
	 	 	 
	 		 
	Name:	 	 
	Title:	 	 

 

    	 	6	 

    	 

    

 

Schedule
1

Representation
and Warranties

  

The
buyer represents and warrants that it has the authority to enter into this transaction. No other representations or warranties
are given or implied.

  

The
seller represents and warrants that it has the authority to enter into this transaction. No other representations or warranties
are given or implied.

 

    	 	7Exhibit
10.3

 

COLLABORATION
AGREEMENT

 

THIS
COLLABORATION AGREEMENT (“Agreement”) is made and entered into as of December 17, 2019 (the “Effective
Date”)

 

BETWEEN:

 

GENECOR
AI INC., a corporation formed under the laws of the 

Province of Ontario (“GENECOR”);

 

-and-

 

FRELII
INC., a corporation formed under the laws of the State of Utah; (“FRELII”)

 

WHEREAS
Frelii has developed certain proprietary Artificial Intelligence software platforms in the area of biomedical analysis; and

 

WHEREAS
Frelii has agreed to grant to Genecor certain rights to act as Frelii’s authorized sales representative, or to directly
sublicense, products relating to Frelii’s software platforms within the Territory, subject to the terms and conditions of
this Agreement.

 

NOW
THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth in this Agreement, and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be
legally bound, hereby agree as follows:

 

Article
I

GENERAL MATTERS

 

	1.1	Definitions.

 

In
this Agreement, the following terms will have the meanings set out below unless the context requires otherwise:

 

“Affected
Obligations” has the meaning set forth in Section 14.1(a).

 

“Affiliate”
of a Party means any other individual, corporation, partnership, joint venture, limited liability company, Governmental Authority,
unincorporated organization, trust, association or other entity that directly or indirectly, through one or more intermediaries,
controls, is controlled by, or is under common control with, such individual, corporation, partnership, joint venture, limited
liability company, Governmental Authority, unincorporated organization, trust, association or other entity. The term “control”
(including the terms “controlled by” and “under common control with”) means the possession, directly or
indirectly, of the power to direct or cause the direction of the management and policies of an individual, corporation, partnership,
joint venture, limited liability company, Governmental Authority, unincorporated organization, trust, association or other entity,
whether through the ownership of voting securities, by contract or otherwise.

 

“Agreement”
means this Collaboration Agreement.

 

    	 	 	 

    	 	2	 

    

 

“Applicable
Law” means any domestic or foreign statute, law (including the common law), ordinance, rule, regulation, restriction,
by-law (zoning or otherwise), order or any consent, exemption, approval or license of any Governmental Authority, that applies
in whole or in part to the transactions contemplated by this Agreement, the Products, Genecor, Frelii and their respective Affiliates,
including, without limitation, the Controlled Drugs and Substances Act (SC 1996, c 19), the Cannabis Act and the Regulations,
as the same may be amended, modified or replaced from time to time.

 

“Audit”
has the meaning set forth in Section 8.2(a).

 

“Audit
Report” has the meaning set forth in Section 8.2(c).

 

“Bankruptcy
Proceeding” means, in relation to a Party: (a) the making of an assignment or arrangement for the benefit of creditors;
(b) the filing by such Party of a petition or commencement of proceedings under any bankruptcy or similar law, or having such
a petition filed or proceeding commenced with respect to such Party by another person, where such petition or proceeding of such
other person is not dismissed for a period of 90 calendar days; (c) the levy of an attachment for execution against the whole
or any material part of its assets; (d) such Party becoming insolvent or unable to pay its debts as they generally become due
as determined by a court of competent jurisdiction; or (e) such Party stops, suspends or threatens to stop or suspend payment
of all or a material part of its indebtedness or begins negotiations or takes any other step with a view to the deferral, rescheduling
or other readjustment of all or a material part of its indebtedness.

 

“Board
of Directors” means the Board of Directors of Frelii Inc., as the same may be changed, modified, or replaced from time
to time.

 

“Cannabis
Act” means Bill C-45 “An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the
Criminal Code and other Acts” (Canada), as amended from time to time and as the same may come into force, and includes
all written publicly available notices, guidance, guidelines and ancillary rules or regulations promulgated thereunder or in connection
therewith.

 

“Change
of Control” means with respect to Genecor (i) the acquisition of securities of Genecor representing more than 50% of
the combined voting power of Genecor’s then outstanding securities by any person or group of persons, (ii) the consummation
of a merger or consolidation of Genecor with or into another entity in which a majority of the voting power of the capital stock
of the continuing or surviving entity will be owned by the persons who were Genecor’s equity holders immediately prior to
such merger or consolidation in substantially the same proportions as their ownership immediately prior to such merger or consolidation,
(iii) the dissolution, liquidation or winding up of Genecor, or (iv) the sale, transfer or other disposition of all or substantially
all of the assets of Genecor.

 

“Change
of Law” has the meaning set forth in Section 14.1(a).

 

“Change
of Law Amendment” has the meaning set forth in Section 14.1(b).

 

“Change
of Law Notice” has the meaning set forth in Section 14.1(a).

 

“Change
Period” has the meaning set forth in Section 14.1(b).

 

    	 	 	 

    	 	3	 

    

 

“Confidential
Information” means non-public, confidential, personal or proprietary information concerning a Party and its Affiliates
and its and their respective businesses and affairs that is or has been disclosed by one Party (a “Disclosing Party”)
to the other Party (the “Recipient”) in connection with the transactions contemplated by this Agreement, including
the existence of, the terms and conditions of, the status of the transaction contemplated by, or any other facts pertaining to,
this Agreement, any information about identifiable individuals or any other information relating to a Party and its Affiliates,
customers, suppliers, partners, investors, employees and consultants, but in each case does not include: (a) information that
the Recipient can demonstrate: (i) is or has become generally available to the public other than as a result of disclosure by
the Recipient or its Affiliates or representatives; (ii) is received by the Recipient or its Affiliates or representatives from
an independent third-party that obtained it lawfully and was under no duty of confidentiality; (iii) was in its possession or
the possession of its Affiliates or representatives prior to the disclosure of such information by the Disclosing Party; (iv)
was independently developed by the Recipient or its Affiliates or representatives without the use of or reference to any Confidential
Information; or (v) is disclosed pursuant to a valid and enforceable order of a court or other Governmental Authority having jurisdiction
over a Recipient provided that the Recipient shall, to the extent possible, first notify the Disclosing Party in writing of such
requirement and fully cooperate with respect to any reasonable steps possible to further protect the Confidential Information;
nor (b) any information that is disclosed pursuant to a written or verbal demand from a Governmental Authority provided that the
Recipient shall, to the extent possible, first notify the Disclosing Party of such requirement.

 

“Designated
Representative” has the meaning set forth in Section 9.1(a).

 

“Documentation”
means any reports, analyses, scripts, code or other work results which have been delivered by Frelii to Genecor pursuant to this
Agreement.

 

“Effective
Date” has the meaning set forth in the recitals.

 

“End-User”
means each entity located within the Territory who, for its own internal business purposes (not for resale or use in a time-sharing
arrangement with others) obtains the Products directly from Genecor or its Subcontractor, or directly from Frelii but pursuant
to a purchase order secured by Genecor in its capacity as of sales representative under Section 2.1(b) hereof, for use solely
within the Field and within the Territory.

 

“End-User
License Agreement” means the then-current electronic “click-through” license or other end-user license between
End-User and Frelii or a third party Software manufacturer, as applicable, governing End-User’s use of the Products. All
such End-User License Agreements shall be on a form provided, or otherwise approved, by Frelii or the third party Software manufacturer,
as applicable.

 

“Event
of Default” has the meaning set forth in Section 15.3.

 

“Field”
means genetic testing of patients for the purpose of selection and use of cannabis for medical purposes.

 

“Frelii
Property” means all rights of Intellectual Property in and to the Products or Documentation (including all derivatives
or improvements thereof), any patents, processes, software, code, files, technology, templates, forms, scripting, trade secrets,
any Frelii products, reports, ideas, concepts, operations, plans or intentions, know-how, market opportunities, customers, business
affairs, development plans and financial information, any suggestions, information, enhancements, requests, feedback, recommendations
or other input provided by any person or party relating to the Products or Documentation, and any such item created by Frelii
in developing or providing the Products.

 

“Governmental
Authority” means any: (a) multinational, national, federal, provincial, territorial, state, regional, municipal, local
or other government or any governmental or public department, court, tribunal, arbitral body, statutory body, commission, board,
bureau or agency; (b) self-regulatory organization, regulatory authority, administrative tribunal or authority; (c) subdivision,
agent, commission, board or authority of any of the foregoing; or (d) quasi-governmental or private body exercising any regulatory,
expropriation or taxing authority under or for the account of any of the foregoing.

 

    	 	 	 

    	 	4	 

    

 

“Gross
Revenue” means all revenue and other cash or like forms of consideration (accounted for in accordance with GAAP) that
is (i) received by, paid to or for the account of, or for the benefit of Genecor (including as may be paid to Genecor Affiliates,
representatives, Subcontractors, employees, directors or agents) and generated, directly or indirectly, from the resale of the
Products in accordance with Section 2.1(a) hereof, or (ii) received by, paid to or for the account of, or for the benefit of Frelii
as a result of a sale of Products resulting solely and exclusively from to a purchase order secured by Genecor in its capacity
of sales representative under Section 2.1(b). For the avoidance of doubt, “Gross Revenue” shall include, but shall
in no way be limited to, revenues (in any form) received for Product pilots, evaluations, and trials, royalties, commissions,
and consulting fees, and such other ancillary revenues generated (directly or indirectly) by the sale or licensing of the Products
or any solicitation for such.

 

“Indemnified
Party” has the meaning set forth in Section 13.1(a).

 

“Indemnifying
Party” has the meaning set forth in Section 13.1(a).

 

“Intellectual
Property” means patents, rights to inventions, copyright and related rights, moral rights, trademarks and service marks,
trade names and domain names, rights in get-up, rights to goodwill or to sue for passing off or unfair competition, rights in
designs, rights in computer software, database rights, rights in confidential information (including know-how and trade secrets)
and any other intellectual property rights, in each case whether registered or unregistered and including all applications (or
rights to apply) for, and renewals or extensions of, such rights and all similar or equivalent rights or forms of protection which
subsist or will subsist now or in the future in any part of the world.

 

“International
Territory” means all countries throughout the world, except the Canadian and US Territories.

 

“Losses”
means any loss, injury, liability, damage, cost, expense (including reasonable legal and consulting fees and disbursements), suffered
or incurred by a Party, including in respect of any proceeding, assessment, judgment, settlement or compromise relating thereto.

 

“Minimum
Sales Quota” means, with respect to Canada, an 18-month rolling average of Gross Revenue equal to $1,000,000 for the
initial term. Subsequent targets shall be set annually and mutually agreed amongst the parties.

 

“Genecor”
has the meaning set forth in the recitals.

 

“Genecor
Initial Application” has the meaning set forth in Section 6.1(b).

 

“Overpayment”
has the meaning set forth in Section 8.2(d).

 

“Parties”
means Genecor and Frelii and “Party” means either one of them.

 

“Products”
means Software provided or made available by Frelii to Genecor for distribution or solicitation for sale under this Agreement,
as more specifically described on Exhibit A hereto, which Exhibit may be updated by Frelii from time to time in its sole
discretion.

 

“Records”
means all ancillary, intermediate and final documents, work product, records, reports, manuals, notes, designs, specifications,
configurations and materials prepared by Genecor or any of its Affiliates or representatives in connection with the transactions
contemplated by this Agreement including all books, records, logs, files, assessments and reports relating to: (a) the Sales Reports;
(b) the Products; (c) Gross Revenue; (d) Approved Operating Costs; and/or (e) the Minimum Sales Quota.

 

    	 	 	 

    	 	5	 

    

 

“Records
Request” has the meaning set forth in Section 8.1(c).

 

“Regulations”
means the Access to Cannabis for Medical Purposes Regulations (SOR/2016-230), as the same may be amended, modified or replaced
from time to time, and similar regulations in other parts of the Territory.

 

“Regulatory
Approval” means all requisite approvals by a Regulatory Authority, including but not limited to Health Canada, for Genecor
to market, advertise, promote, and sublicense the Products or solicit the same for sale.

 

“Regulatory
Authority” means any applicable government entity regulating or otherwise exercising authority with respect to the development
and commercialization of the Products.

 

“Retention
Period” has the meaning set forth in Section 8.1(b).

 

“Sales
Reports” has the meaning set forth in Section 7.2(a).

 

“Shares”
means all of the common and preferred shares and other equity securities of Genecor, regardless of class.

 

“Software”
means, Navii, Frelii’s Artificial Intelligence software platform proprietary to Frelii or third party software as the case
may be as a service platforms that Frelii has the right to license or otherwise distribute, together with any additional features
or functionality developed by Frelii for general use that augment or enhance such platform.

 

“Third
Party” has the meaning set forth in Section 2.2.

 

“Underpayment”
has the meaning set forth in Section 8.2(d).

 

	1.2	Currency

 

Unless
otherwise indicated, all dollar amounts referred to in this Agreement are stated in lawful money of the United States and “$“
refers to United States dollars. Where Products are licensed or sublicensed for monies other than United States dollars, payments
will first be determined in the foreign currency of the country in which the Products are licensed or sublicensed, then converted
into equivalent United States dollars. The exchange rate will be the United States dollar buying rate quoted in the Wall Street
Journal on the last day of the reporting period.

 

	1.3	Interpretation
                                         Not Affected by Headings or Party Drafting

 

The
division of this Agreement into articles, sections, paragraphs, subparagraphs and clauses and the insertion of headings are for
convenience of reference only and shall not affect the construction or interpretation of this Agreement. The terms “hereof”,
“herein”, “hereunder” and similar expressions refer to this Agreement hereto and not to any particular
article, section, paragraph, clause or other portion hereof and include any agreement or instrument supplementary or ancillary
hereto. The Parties acknowledge that their respective legal counsel have reviewed and participated in settling the terms of this
Agreement and the Parties hereby agree that any rule of construction to the effect that any ambiguity is to be resolved against
the drafting Party shall not be applicable in the interpretation of this Agreement.

 

    	 	 	 

    	 	6	 

    

 

	1.4	Inclusive
                                         Language

 

The
words “include”, “includes” and “including” and other derivations thereof shall be read as
if followed by the phrase “without limitation”.

 

	1.5	Number
                                         and Gender

 

In
this Agreement, unless there is something in the subject matter or context inconsistent therewith: (a) words in the singular number
include the plural and such words will be construed as if the plural had been used; (b) words in the plural include the singular
and such words will be construed as if the singular had been used; and (c) words importing the use of any gender include all genders
where the context or Party referred to so requires, and the rest of the affected sentence will be construed as if the necessary
grammatical and terminological changes had been made.

 

	1.6	Statutory
                                         References

 

In
this Agreement, unless something in the subject matter or context is inconsistent therewith or unless otherwise herein provided,
a reference to any statute is to that statute as now enacted or as the same may from time to time be amended, re-enacted or replaced
and includes any regulations made thereunder.

 

Article
II

GRANT
OF RIGHTS

 

	2.1	Subject
                                         to the terms of this Agreement, Frelii hereby appoints Genecor, and Genecor hereby accepts
                                         such appointment:

 

	 	(a)	As
    Frelii’s independent, authorized sublicensor during the Term, with the exclusive right to market, license and distribute
    the Products to End-Users in Canada, and
	 	 	 
	 	(b)	To
    act, during the Term, as the exclusive independent sales representative of the Products to End-Users in Canada.

 

	2.2	In
                                         exercising the rights granted to it under Section 2.1 hereof, Genecor may, with the prior
                                         written consent of Frelii, elect to engage additional subcontractors to assist in fulfilling
                                         Genecor’s obligations hereunder (each, a “Subcontractor”).
                                         Genecor shall enter into a written agreement with each Subcontractor, in a form to be
                                         approved in advance by Frelii, requiring that such Subcontractor comply with all applicable
                                         terms and conditions of this Agreement, and naming Frelii as an intended third party
                                         beneficiary of such written agreement. Notwithstanding anything herein to the contrary,
                                         Genecor shall bear full responsibility for any acts or omissions of any Subcontractor,
                                         and the engagement by Genecor of any Subcontractor shall in no way relieve Genecor of
                                         any duty, obligation, or liability set forth in or arising out of this Agreement. Genecor
                                         shall not grant any rights of exclusivity to any Subcontractor without the express prior
                                         written consent of Frelii.

 

	2.3	During
                                         the Term, Frelii will not, directly or indirectly, permit, license or appoint any other
                                         person, firm, business entity, corporation or other third party (“Third
                                         Party”) (i) to license, market or distribute
                                         the Products to End-Users in Canada, or (ii) to act as a sales representative of the
                                         Products to End-Users in Canada.

 

    	 	 	 

    	 	7	 

    

 

	2.4	If
    Frelii receives notice from Genecor that a Third Party is (i) licensing, marketing or distributing the Products to End-Users
    in Canada, or (ii) acting as a sales representative of the Products to End-Users in Canada, Frelii shall immediately notify
    such Third Party to forthwith cease and desist from engaging in such activities in Canada. Frelii shall take such steps or
    legal proceedings as it deems reasonably necessary or advisable, as determined in its sole discretion.
	 	 
	2.5	Frelii
    agrees that throughout the Term, Frelii shall use its commercially reasonable efforts to direct all legitimate inquiries from
    within Canada with respect to the Products, which may come directly to it, to Genecor for completion of such licenses.
	 	 
	2.6	Genecor
    agrees that neither Frelii nor anyone acting on its behalf or purporting to represent it have made any representations or
    agreements to induce it to enter into this Agreement. No representations have been made concerning prospects for successful
    operations, the level of business or profits that Genecor might reasonably expect, or similar matters, all of which Genecor
    acknowledges are dependent upon variables beyond Frelii’s control, including, without limitation, the ability, motivation,
    and amount and quality of effort expended by Genecor. Genecor hereby releases Frelii, its affiliates, officers, directors,
    employees or agents from any claims, suits or demands related to any such representations or risk of operations of the business.
    Specifically, Genecor agrees that Frelii has made no guarantees or representation that: (i) it will find customers or locations
    for Genecor, or (ii) it will purchase products or services from Genecor, or (iii) Genecor will or may derive income of any
    particular level or will provide a program which will enable Genecor to derive income of any particular level, or (iv) that
    it will provide a marketing plan for Genecor, or (v) that there is a market for the Products.

 

Article
III

GENECOR
OBLIGATIONS

 

	3.1	With
    respect to the rights granted it under Section 2.1(a), Genecor shall order the DNA kits directly from Frelii by submitting
    written or electronic purchase orders, signed or otherwise authorized by an authorized representative of Genecor (each, an
    “Order”).
    Each Order must designate the Products and quantity desired, applicable price, and requested delivery dates. An Order is binding
    for both Parties when Frelii has accepted the Order by either sending an e-mail or other writing, or by making the Products
    available to Genecor. Frelii shall provide to Genecor its list of products and update thereto on a timely basis.
	 	 
	3.2	Genecor
    shall, in good faith:

 

	 	(a)	Market,
    advertise, promote, and sublicense or solicit for license, as the case may be, the Products to End-Users in the Territory
    consistent with good business practice, in each case using its commercially reasonable efforts to maximize the volume of the
    Products licensed;
	 	 	 
	 	(b)	Initiate
    and attend calls and meetings with prospective and existing customers;
	 	 	 
	 	(c)	Have
    sufficient knowledge of the industry and products competitive with the Products (including specifications, features and benefits)
    so as to be able to explain in detail to the End-User (i) the differences between the Products and competing products, and
    (ii) information on standard protocols and features of the Products;
	 	 	 
	 	(d)	Promptly
    inform Frelii of any legal requirements in the Territory relating to the use or distribution of the Products or marketing
    materials;

 

    	 	 	 

    	 	8	 

    

 

	 	(e)	Market,
    advertise, promote, sublicense and solicit for license the Products and conduct business in accordance with Applicable Law,
    and in a manner that reflects favorably at all times on the Products and the good name, goodwill, and reputation of Frelii;
	 	 	 
	 	(f)	Provide,
    at its own cost and expense, adequate End-User support as more specifically set forth in Section 3.5; and
	 	 	 
	 	(g)	Promptly
    (i) notify Frelii of any complaint or adverse claim about any Product or its use of which Genecor becomes aware, and (ii)
    diligently resolve, at its expense and to Frelii’s reasonable satisfaction, such complaint or adverse claim. In connection
    with the foregoing, Frelii agrees to provide to Genecor, [at no additional cost], any data reasonably available on Frelii’s
    systems and that is required by Genecor for the research and resolution of such complaints and adverse claims.
	 	 	 
	 	(h)	Genecor
    has agreed it may assist in capital funding initiatives for Frelii. Any capital raised will be invested directly into Frelii
    will be taken into consideration when developing targets for the ensuing business plan. For added clarity, the capital raised
    will be grossed-up proportionately to offset the volume targets established by the parties. Genecor shall be entitled to participated
    in the capital raised commensurate to the equity investment held by Frelii at that time.

 

	3.3	Notwithstanding
    anything to the contrary in this Agreement, neither Genecor nor its representatives, Subcontractors, affiliates, agents, or
    personnel will:

 

	 	(a)	Make
    any representations, warranties, guarantees, service level commitments, indemnities, similar claims, or other commitments
    (i) actually, apparently, or ostensibly on behalf of Frelii; or (ii) with respect to the Products, that are in addition to
    or in any way inconsistent with any then-existing representations, warranties, guarantees, service level commitments, indemnities,
    similar claims, or other commitments in this Agreement or any written documentation provided by Frelii to Genecor;
	 	 	 
	 	(b)	Attempt,
    in any way, to circumvent the revenue sharing provisions of Article VII, or to hide, re-direct, disguise, obscure, withhold,
    omit, mischaracterize, or in any way seek to exclude from inclusion in “Gross Revenue” any compensation Genecor
    may receive, in any form, in connection with this Agreement;
	 	 	 
	 	(c)	Engage
    in any unfair, competitive, misleading, or deceptive practices respecting Frelii, Frelii’s trademarks or the Products,
    including any product disparagement;
	 	 	 
	 	(d)	Remove,
    translate, or in any way modify the contents or documentation of any Software, including, without limitation, any end user
    license agreement or warranty statements; or
	 	 	 
	 	(e)	Subject
    to Section 2.2, hereof, sell, either directly or indirectly, or assign or transfer, any Products to any person or entity when
    Genecor knows or has reason to suspect that the person or entity may sublicense any or all of the Products to a Third Party.

 

	3.4	Genecor
    shall be responsible for, and shall promptly provide at its own cost and in accordance with industry standards, all direct
    End-User support, including, without limitation, implementation and configuration services, technical support, Product trainings,
    and general Product information. Notwithstanding the foregoing, Frelii agrees to provide to Genecor, employee training and
    consultation services with respect to complex technical questions.

 

    	 	 	 

    	 	9	 

    

 

	3.5	With
    respect to the exercise of the rights granted to Genecor under Sections 2.1(a)(i) and 2.1(b)(i) hereof, and beginning on the
    date that is eighteen (18) months after the Effective Date, Genecor shall meet the Minimum Sales Quota of $1M. In the event
    Genecor fails to achieve the Minimum Sales Quota, Frelii shall have the right to convert the rights granted to Genecor pursuant
    to Sections 2.1(a)(i) and 2.1(b)(i) from exclusive to non-exclusive after giving a proper and agreed cured period not to be
    less than 6 months. This change in non-exclusivity will be on a country by country basis (e.g. only apply to the jurisdiction
    in which the Minimum Sales Quota was not achieved). The Minimum Sales Quota may be modified or amended from time to time by
    written agreement of the Parties. To avoid any potential disagreement, the parties agree to hold joint business planning sessions
    to develop, monitor and achieve Sales Quota targets.
	 	 
	3.6	Notwithstanding
    anything to the contrary herein, Genecor is prohibited from selling or licensing, or soliciting for sale or license, the Products
    to any known or suspected competitor of Frelii. Frelii shall have the absolute right to deny or void, at its discretion and
    with no liability to Genecor, any transaction proposed or contemplated in connection with this Agreement, the effect of which
    would be the provision, or possible provision, of Products to any competitor of Frelii. Genecor shall ensure that any written
    agreement entered into between Genecor and any End-User, Subcontractor, or other third party with respect to the Products,
    contains language (i) prohibiting the provision or transfer of Products to any competitor or suspected competitor of Frelii,
    (ii) granting to Frelii and Genecor an absolute termination right for any breach of such restriction, and (iii) naming Frelii
    as an intended third party beneficiary under such agreement.
	 	 
	3.7	Genecor
    shall comply with all Applicable Laws in performance of its obligations hereunder. As between Genecor and Frelii, Genecor
    shall be solely and absolutely responsible for compliance with local laws and regulations in the marketing, advertising, promotion,
    sale, and sublicensing, and the solicitation for sale and licensing, of the Products. Genecor will suggest to Frelii such
    updates to the Products as is necessary to comply with local law, and Genecor agrees to reimburse Frelii for the cost of making
    any such updates. Frelii disclaims any and all responsibility for legal compliance in the International Territory.

 

Article
IV

LICENSES

 

	4.1	Subject
    to the terms of this Agreement and for the sole and exclusive purpose of exercising the rights granted to it pursuant to Section
    2.1(a), Frelii grants to Genecor (i) a limited, personal, non-exclusive, non-transferable, revocable right to distribute the
    licenses of the Products to End-Users, subject to the End-User License Agreement, and (ii) a limited, royalty-free, non-exclusive,
    non-transferable, revocable license to distribute the then-current, generally available Documentation (to the extent such
    exists) to End-Users in conjunction with the distribution of the applicable ordered Products, solely for the purpose of supporting
    the End-User’s use of the applicable ordered Products.
	 	 
	4.2	From
    time to time, Frelii may provide Genecor (in connection with the rights granted to Genecor pursuant to Section 2.1) with demonstration
    materials, including without limitation, prototypes of the Products, technical manuals, software, Documentation or materials
    (“Demonstration Materials”),
    to be provided to prospective customers for the purpose of evaluating the Products. Frelii hereby grants to Genecor a limited,
    personal, non-exclusive, non-transferable, revocable right to use the Demonstration Materials to demonstrate the Products
    to prospective customers in strict accordance with all of the terms of this Agreement and solely to the extent necessary to
    fulfill the purposes of this Agreement. Except where Demonstration Materials disclosed contain only publicly available information,
    prior to the disclosure of any Demonstration Materials to a prospective customer, Genecor shall require such prospective customer
    to execute a non-disclosure agreement in a form reasonably satisfactory to Frelii.

 

    	 	 	 

    	 	10	 

    

 

	4.3	The
    rights granted to Genecor with respect to the Products and Documentation are that of a license only. No title to, or ownership
    of, the Products or Documentation is transferred to Genecor. As between Genecor and Frelii, Frelii shall at all times be and
    remain the sole and exclusive owner of all Frelii Property. Frelii shall be under no obligation to update or modify the Products
    or Documentation in any way. In providing the Products and Documentation hereunder, Frelii does not and shall not be deemed
    to transfer to Genecor or End-User any intellectual property rights therein, whether as “work-for-hire” or otherwise,
    other than the right to use the same in accordance with this Agreement. Should Genecor be deemed to acquire any ownership
    interest in the Products or Documentation or any other Frelii Property, Genecor hereby assigns, grants and conveys to Frelii
    all right, title and interest in and to any and all such Products, Documentation or other Frelii Property. Genecor will execute
    and deliver to Frelii such further assignments and take all such further actions as Frelii may reasonably request to effect
    or evidence the assignment to and vesting in Frelii of all such rights. All rights not expressly granted to Genecor under
    this Agreement are reserved by Frelii. Genecor shall reproduce and include copyright and other proprietary notices on and
    in any copies, including but not limited to partial, physical or electronic copies of Products and/or Documentation.
	 	 
	4.4	Except
    for the licenses expressly granted to Genecor hereunder, no rights are granted and none shall be implied. Genecor shall not,
    nor shall it permit any third party to: (i) cause or permit the copying or reproduction of the Products or Documentation;
    (ii) translate, adapt, enhance, supplement, vary or modify the Product or Documentation; (iii) disclose the Product or Documentation
    to any third party; (iv) use or access the Products or Documentation to build or support, and/or assist a third party in building
    or supporting and services competitive to Frelii; (v) remove any proprietary notices or labels from the Products or Documentation;
    (vi) disassemble, decompile or reverse engineer the Products or create any derivative works based thereon; or (vii) lease
    or enter into any time share, outsourcing, or service bureau arrangement with respect to the Products.
	 	 
	4.5	In
    its exercise of its rights under Section 4.1, Genecor may, upon the prior written approval of Frelii and subject to any reasonable
    Frelii policies, market, advertise, promote, sublicense or solicit for license the Products under its own name, brand, and
    trademarks; provided, however, any and all such activities shall be and remain subject to the terms and conditions of this
    Agreement.
	 	 
	4.6	All
    Product licenses granted herein are for use of object code only. Genecor shall not, without Frelii’s prior written consent
    (i) use Products in a service bureau, application service provider or similar capacity; or (ii) disclose to any third party
    the results of any comparative or competitive analyses, benchmark testing or analyses of Frelii Products performed by or on
    behalf of Genecor or End-Users.
	 	 
	4.7	Genecor
    shall not, without the prior, express written consent of Frelii, incorporate any portion of the Frelii Property, including
    but not limited to the Products, in any Genecor products or services.
	 	 
	4.8	In
    connection with the licenses granted herein, Frelii agrees to:

 

	 	(a)	Issue,
    from time to time and in its sole discretion, updates, revisions, improvements, modifications, enhancements, bug fixes, patches
    or other error corrections with respect to the Products or the Frelii platform as necessary to maintain the Products and to
    facilitate proper functioning thereof;

 

    	 	 	 

    	 	11	 

    

 

	 	(b)	Provide
    hosting services with respect to the Products; provided that Frelii reserves the right to bill Genecor or the End-User (and
    Genecor agrees to pay or to require the End-User to pay, as the case may be) a reasonable fee for such hosting services; Frelii
    and Genecor acknowledge that providing such hosting services may require or be conditioned on the execution of a separate
    hosting agreement; It is hereby agreed that until such time that Genecor has established sufficient volumes, Frelii will provide
    all hosting services and support. Parties agree to discuss SLA’s and execute a separate agreement with duties and responsibilities
    or each party.
	 	 	 
	 	(c)	Provide
    Genecor employee training and consultation services with respect to complex technical questions in accordance with the provisions
    of Section 3 hereof; and
	 	 	 
	 	(d)	Provide
    customization and implementation services, provided that the terms (including compensation) for the provision of such customization
    and implementation services shall be negotiated on a case-by-case basis by the Parties, and shall in each case be memorialized
    in a separate, executed statement of work.

 

Article
V

WARRANTIES

 

	5.1	Frelii
    makes no representations or warranties whatsoever with respect to the Products, Documentation, or Demonstration Materials,
    or any services rendered by it hereunder, except to the extent explicitly provided in the End-User License Agreement. Frelii’s
    entire liability and Genecor’s and any End-User’s exclusive remedies with respect to the Frelii representations
    and warranties shall be as set forth in the End-User License Agreement.
	 	 
	5.2	THE
    WARRANTIES, IF ANY, IN THIS SECTION 5 CONCERNING THE PRODUCTS ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH
    RESPECT TO THIS AGREEMENT OR THE PRODUCTS. FRELII (INCLUDING ITS SUPPLIERS) MAKES NO OTHER EXPRESS OR IMPLIED WARRANTIES,
    OR CONDITIONS WRITTEN OR ORAL. INSOFAR AS PERMITTED UNDER APPLICABLE LAW, ALL OTHER WARRANTIES ARE SPECIFICALLY EXCLUDED,
    INCLUDING ANY IMPLIED WARRANTIES OR CONDITIONS ARISING BY STATUTE, COURSE OF DEALING, OR USAGE OF TRADE, INCLUDING BUT NOT
    LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT.

 

Article
VI

DEVELOPMENT

 

	6.1	Licensing.

 

	 	(a)	It
    is acknowledged that the sale of the Products in the Territory may need to be registered or licensed as contemplated under
    the Regulations and pursuant to the laws of other jurisdictions in the Territory, and Genecor shall be responsible for obtaining
    all such requisite approvals and licenses.
	 	 	 
	 	(b)	Frelii
    agrees that it will provide reasonable assistance to Genecor in preparing the necessary items to submit an application from
    Genecor to Health Canada and other Regulatory Authorities to obtain all necessary approvals permitting Genecor to market,
    advertise, promote, and sublicense or solicit for license, as the case may be, the Products (the “Genecor Initial
    Application”) in the Territory and, subject to and in accordance with all Applicable Laws and the Regulations.
	 	 	 
	 	(c)	Genecor
    shall be responsible for all costs, expenses and fees payable: (i) to third-party consultants which have been sourced and
    hired in relation to the Genecor Initial Application; (ii) to any Governmental Authority in respect of the Genecor Initial
    Application; and (iii) otherwise payable to complete and submit the Genecor Initial Application.

 

    	 	 	 

    	 	12	 

    

 

Article
VII

PAYMENT TERMS

 

	7.1	Fees

 

	 	7.1.1	Profit
    Participation
	 	 	 
	 	(a)	Unless
    otherwise agreed to by the Parties in writing, Frelii shall earn 25% (Twenty Five Percent) of all Normalized Net Income generated
    by Genecor in Canada. Normalization adjustments shall be defined and agreed upon by the parties on an annual basis. Payments
    of the foregoing shall be made as follows:

 

	 	(i)	Within15
    calendar days after the close of each Month, Genecor shall deliver to Frelii a Sublicensing Report in the form specified in
    Section 7.2 below, and (y) any Sublicensing Payment Transfers due by Genecor to Frelii as set forth in such Sublicensing Report.

 

	 	7.1.2	License
    Fee
	 	 	 
	 	(b)	A
    USD 750,000 one time license fee shall be paid by Genecor or its parent to Frelii within the terms as agreed in the binding
    term sheet dated December 17, 2019.

 

	7.2	Profit
    Participation Payments.

 

	 	(a)	Financial
    Statements.
	 	 	 	 
	 	 	(i)	On
    a monthly basis, Genecor shall furnish to Frelii financial statements, including Profit and Loss and Balance Sheet no later
    than 15 days
	 	 	 	 
	 	 	(ii)	On
    a quarterly basis, Genecor shall furnish to Frelii U.S. GAAP financial statements, including Profit and Loss, Balance Sheet,
    Cashflow Statement and other reports that may be reasonably required to support Frelii’s public disclosure requirements
    or auditor requests.

 

	7.3	Confidentiality
	 	 
	 	Any
    and all information, data or reports supplied by a Party pursuant to the provisions of this Article VII shall be treated as
    such Party’s Confidential Information.

 

    	 	 	 

    	 	13	 

    

 

	7.4	Payment
    Method.
	 	 
	 	Unless
    otherwise agreed by the Parties, all amounts due under this Agreement will be paid by wire transfer in immediately available
    funds to accounts designated in writing by the Parties.
	 	 
	7.5	Taxes

 

	 	(a)	All
    payments hereunder shall be exclusive of any taxes eligible thereon including. Any such taxes shall be borne solely by the
    payor and Genecor shall pay any taxes owing to Frelii simultaneously with, and in addition to, any other payments contemplated
    by this Agreement, if eligible.
	 	 	 
	 	(b)	Subject
    to any Applicable Laws, the Parties shall cooperate with each other to minimize each other’s applicable taxes and each
    Party shall use its commercially reasonable efforts to provide the other Party with any reasonable certificates or documents
    which are useful for such purpose.

 

	7.6	International
    Rights

 

	 	(a)	This
    agreement grants licensing Rights for International Territory. Both parties agree that if Genecor or Frelii is approached
    by a third party looking to acquire the rights for a territory, Genecor will act as the lead negotiating party.
	 	 	 
	 	(b)	Licensing
    Rights for International Territory. Frelii agrees that it will not sell or issue or agree to sell or issue Licensing Rights
    for any International Territory. It further agrees to allow Gencor to facilitate the granting of licensing rights of the International
    Territory. Frelii and Genecor shall own any International Territory rights equally.
	 	 	 
	 	(c)	Any
    expansion of Genecor outside of Canada will be in the form of a Joint venture structure through the formation of a new entity
    on a country by country basis. Each party will be entitled to participate equally unless otherwise agreed and have a joint
    and equal say with respect to matters relating to strategy, governance and operations. The same rights, privileges , duties
    and responsibilities will deem to apply unless otherwise agreed. Parties agree that depending on local law and rules some
    modification may be required, otherwise it is understood the spirit and intent of all provisions in the agreement are intended
    to apply and remain in force for the duration of the licensing agreement.

 

	7.7	Genecor
    Board of Directors
	 	 
	 	During
    the Term hereof, Frelii shall have the authority to appoint no less than 2 of the number of Directors constituting Genecor’s
    Board of Directors, as the size of such Board of Directors may be modified from time to time.
	 	 
		Frelii
    Board of Directors
	 	 
	 	During
    the Term hereof, Genecor shall have the authority to appoint no less than 1 of the number of Directors constituting Frelii’s
    Board of Directors, as the size of such Board of Directors may be modified from time to time.

 

    	 	 	 

    	 	14	 

    

 

Article
VIII

RECORDS AND AUDIT RIGHTS

 

	8.1	Record
    Retention.

 

	 	(a)	Genecor
    will maintain complete and accurate books, records and accounts that fairly reflects all amounts and information to be disclosed
    in a Sales Report and all of Genecor’s activities related to this Agreement, in sufficient detail to confirm the accuracy
    of any payments required hereunder, including:
	 	 	 	 
	 	 	(i)	such
    documents, Records and other information required by Applicable Law and the provisions of this Agreement;
	 	 	 	 
	 	 	(ii)	detailed,
    accurate, complete and current financial Records regarding the sale of Products during the Term, including the Sales Reports;
	 	 	 	 
	 	 	(iii)	such
    other additional documents, books, Records and other information as may be mutually agreed to in writing from time to time
    by the Designated Representatives of the Parties.
	 	 	 	 
	 	(b)	Genecor
    shall retain accurate and complete copies of all Records for such period of time: (i) as required by Applicable Law; or (ii)
    until five years after the expiration or termination of this Agreement, whichever is greater. Notwithstanding the foregoing,
    Genecor confirms, acknowledges and agrees that it shall, and shall cause each of their respective Affiliates and representatives
    to, retain accurate and complete copies of all financial Records relating to Products or this Agreement until five years after
    the date that all payments which are payable pursuant to the provisions of this Agreement have been paid in full (the “Retention
    Period”).
	 	 	 	 
	 	(c)	At
    any time, and from time to time, during the Term and the Retention Period, Frelii may make a written request for a copy of
    the Records created and maintained by Genecor (a “Records Request”). Genecor shall provide the requested
    Records as soon as reasonably practicable after the date of its receipt of the Records Request and, in any event, no later
    than 30 calendar days after its receipt of the Records Request. For greater certainty, a Records Request shall not be considered
    an Audit for the purposes of this Agreement.

 

	8.2	Audit
                                         Rights.

 

	 	(a)	During
    the Term and for a period of six (6) months thereafter, Frelii shall have the right at its sole cost and expense to inspect
    the books and records of Genecor (including the Records) in respect of all matters pertaining to this Agreement (each an “Audit”)
    upon request, acting reasonably, and as may be mandated by a Regulatory Authority or Applicable Laws.
	 	 	 
	 	(b)	With
    respect to each Audit:

 

	 	(i)	Frelii
    shall provide Genecor with 15 calendar days prior written notice of its intention to conduct such Audit unless Frelii determines,
    in its reasonable discretion, that a shorter notice period is required;

 

    	 	 	 

    	 	15	 

    

 

	 	(ii)	to
    the extent permitted by Applicable Laws, Genecor shall provide Frelii and its external advisors with reasonable access, during
    normal business days and hours, to Genecor’s place of business, its books and records (including the Records), and the
    Designated Representative of Genecor for the purposes of conducting the Audit;

 

	 	(iii)	Frelii
    confirms and acknowledges that Frelii and its external advisors will at all times be accompanied by a representative of Genecor;
	 	 	 
	 	(iv)	the
    Audit shall be conducted as efficiently as possible and with as little disruption to the business operations of Genecor as
    reasonably possible;
	 	 	 
	 	(v)	as
    a condition precedent to the obligation of Genecor to grant Frelii’s external advisors access to Genecor’s premises
    and books and records (including the Records), such external advisors must first execute a confidentiality agreement in favor
    of Genecor in a form reasonably satisfactory to Genecor which provides for obligations of confidentiality which are substantially
    similar to the obligations of confidentiality provided for in Section 12.1; and
	 	 	 
	 	(vi)	all
    costs and expenses incurred by Frelii in connection with such Audit shall be for the sole account of Frelii, provided that
    if such Audit reveals an Underpayment which is greater than five percent (5%), Genecor shall reimburse Frelii for such costs
    and expenses promptly upon presentment of an invoice therefor.

 

	 	(c)	The
    results of each Audit (each an “Audit Report”) shall be provided by Frelii to the Designated Representative
    of Genecor within seven calendar days after receipt by Frelii. With respect to each Audit Report, the Designated Representatives
    of the Parties shall meet (in person or by telephone) within 30 calendar days of the provision of the Audit Report to the
    Designated Representative of Genecor in order to discuss the findings of the Audit Report.
	 	 	 
	 	(d)	If
    the Designated Representatives of the Parties mutually agree on the findings set out in the Audit Report, then: (i) any underpayment
    of any fees or other payments which are payable by Genecor pursuant to the provisions of this Agreement during the audited
    period (each an “Underpayment”) shall be promptly paid by Genecor to Frelii in immediately available funds;
    (ii) any overpayment of any fees or other payments which are payable by Frelii pursuant to the provisions of this Agreement
    during the audited period (each an “Overpayment”) shall be set-off against any outstanding or future payments
    to Frelii; and (iii) the Designated Representatives of each Party shall take such other actions as are reasonably necessary
    to address any other item, dispute or deficiency set out in the Audit Report.

 

	8.3	Confidentiality.

 

Each
Party will treat all information subject to review under this Article VIII in accordance with the confidentiality provisions of
Article XII below.

 

    	 	 	 

    	 	16	 

    

 

Article
IX

DESIGNATED REPRESENTATIVES

 

	9.1	Designated
                                         Representative.

 

	 	(a)	Each
    Party shall appoint a representative that will have general oversight and management responsibility for the general administration
    of this Agreement and to whom the questions and concerns of each Party with respect to the rights, obligations and performance
    of this Agreement (each such person a “Designated Representative”) shall be directed in the first instance.
    For greater certainty, each Designated Representative shall have decision-making authority and the ability to bind his or
    her respective Party. As at the Effective Date the Designated Representatives of each Party are as follows:

 

	 	Genecor:	Tejas
    Shah, Director or then-current CEO, as the case may be
	 	 	 
	 	Frelii:	Ian
    Jenkins, or then-current CEO, as the case may be

 

Each
Party may change its Designated Representative upon five business days’ prior written notice of such change to the other
Party.

 

	 	(b)	The
    Designated Representatives of each Party shall:
	 	 	 	 
	 	 	(i)	meet
    at least once during each Calendar Quarter, or otherwise as may be mutually agreed by the Parties;
	 	 	 	 
	 	 	(ii)	generally
    review the performance of this Agreement and facilitate the cooperation of the Parties in the performance of this Agreement;
	 	 	 	 
	 	 	(iii)	maintain
    the Records as contemplated by Article VIII;
	 	 	 	 
	 	 	(iv)	perform
    those obligations designated in this provisions of this Agreement as responsibilities of the Designated Representatives;
	 	 	 	 
	 	 	(v)	have
    overall responsibility for the consideration of any proposed amendment or modification to this Agreement, including, without
    limitation, any Change of Law Amendment; and
	 	 	 	 
	 	 	(vi)	have
    such other responsibilities and obligations or perform such other duties as are expressly contemplated by this Agreement or
    as the Parties may mutually agree in writing from time to time.

 

Article
X

REPRESENTATIONS AND WARRANTIES

 

	10.1	Mutual
    Representations and Warranties.

 

Each
Party hereby represents and warrants to and in favor of, and covenants with, the other Party as follows, and acknowledges that
the other Party is relying upon the following representations, warranties and covenants in connection with its execution, delivery
and performance of this Agreement and the consummation of the transactions contemplated hereunder:

 

	 	(a)	the
    Party is a corporation validly formed and existing in good standing under the laws of its jurisdiction of formation;

 

    	 	 	 

    	 	17	 

    

 

	 	(b)	the
    Party has all necessary power, authority and capacity to enter into this Agreement and to perform its obligations under this
    Agreement. The execution, delivery and performance of this Agreement has been duly authorized by all necessary action of the
    Party. This Agreement has been duly and validly executed by the Party, and constitutes a valid and binding obligation of the
    Party enforceable against it in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency,
    moratorium, reorganization and similar laws affecting creditors generally and by general principles of equity, regardless
    of whether asserted in a proceeding in equity or law;
	 	 	 
	 	(c)	the
    authorization of, execution and delivery of, and the performance by the Party of its obligations under, this Agreement and
    every other agreement or document to be entered into or delivered hereunder, will not constitute or result in the violation
    or breach of or default under, or cause the acceleration of, any obligations of the Party under:

 

	 	(i)	any
    term or provision of the articles, by-laws or other organizational documents of the Party;
	 	 	 
	 	(ii)	the
    terms of any material agreement (written or oral), indenture, instrument or understanding or other obligation or restriction
    to which the Party is a party or by which it is bound, except as would not reasonably be expected to have a material adverse
    effect on the Party’s ability to perform its obligations under this Agreement;
	 	 	 
	 	(iii)	any
    Applicable Law or consent or approval issued by a Governmental Authority, except as would not reasonably be expected to have
    a material adverse effect on the Party’s ability to perform its obligations under this Agreement; or
	 	 	 
	 	(iv)	any
    term or provision of any order of any court applicable to the Party, except as would not reasonably be expected to have a
    material adverse effect on the Party’s ability to perform its obligations under this Agreement;

 

	 	(d)	except
    as contemplated by Article VI, no consent or approval of any Governmental Authority, or filing with or notice to, any Governmental
    Authority, court or other Person, is required in connection with the execution, delivery or performance of this Agreement
    by the Party, except for any such consent, approval, filing or notice that would not have a materially adverse effect on the
    Party’s ability to perform its obligations under this Agreement;
	 	 	 
	 	(e)	there
    are no actions, suits or proceedings, judicial or administrative (whether or not purportedly on behalf of the Party) pending,
    or to the best of the knowledge of the Party after due inquiry, threatened against or affecting the Party at law or in equity,
    or before or by any court or other Governmental Authority, domestic or foreign, that would materially adversely affect the
    Party’s ability to perform its obligations under this Agreement; and
	 	 	 
	 	(f)	there
    are no Bankruptcy Proceedings pending or being contemplated by the Party or, to the best of its knowledge after due inquiry,
    threatened against or affecting the Party.

 

    	 	 	 

    	 	18	 

    

 

Article
XI

LIMITATION OF LIABILITY

 

	11.1	No
                                         Indirect Damages.

 

Except
in the case of a willful or fraudulent misrepresentation under Article X, in no event shall either Party be liable to the other
or any of its Affiliates for any consequential, incidental, indirect, special, punitive or exemplary damages (including, without
limitation, lost profits, business or goodwill) suffered or incurred by such other Party or its Affiliates, whether based upon
a claim or action of contract, warranty, negligence or tort, or otherwise, arising out of this Agreement

 

	11.2	Limitation
                                         on Damages.

 

FRELII’S
TOTAL LIABILITY AND GENECOR’S SOLE AND EXCLUSIVE REMEDY FOR ANY CLAIM OF ANY TYPE WHATSOEVER, ARISING OUT OF THE PRODUCTS,
DOCUMENTATION, DEMONSTRATION MATERIALS, OR OTHER SERVICES PROVIDED HEREUNDER SHALL BE LIMITED TO PROVEN DIRECT DAMAGES CAUSED
BY FRELII’S SOLE NEGLIGENCE IN AN AMOUNT NOT TO EXCEED IN US DOLLARS THE SUM PAID BY GENECOR OR THE APPLICABLE OTHER PARTY
FOR THE SPECIFIC PRODUCT WHICH IS THE SUBJECT OF THE CLAIM OF DAMAGE.

 

Article
XII

CONFIDENTIALITY

 

	12.1	Confidential
    Information

 

	 	(a)	The
    Parties shall treat all Confidential Information as confidential and may not either disclose Confidential Information or use
    it other than for bona fide purposes connected with this Agreement without the prior written consent of the other Party
    to this Agreement, except that consent is not required for disclosure to:
	 	 	 	 
	 	 	(i)	an
    Affiliate of a Party or their respective directors, officers, or employees, as long as they in turn are required to treat
    the Confidential Information as confidential on terms substantially the same as those set out in this Section 12.1;
	 	 	 	 
	 	 	(ii)	accountants,
    professional advisers and bankers and other lenders, whether current or prospective, as long as they are subject to statutory
    professional secrecy rules or similar legal concepts under Applicable Laws or, in turn, are required to treat the Confidential
    Information as confidential on terms substantially the same as those set out in this Section 12.1;
	 	 	 	 
	 	 	(iii)	any
    Governmental Authority having jurisdiction over a Party, to the extent legally required, and then only after, to the extent
    permitted by law, informing the other Parties thereof and, to the extent possible, with sufficient notice in advance to permit
    the other Parties to seek a protective order or other remedy;
	 	 	 	 
	 	 	(iv)	any
    person to the extent required by any Applicable Laws, judicial process or the rules and regulations of any recognized stock
    exchange, and then only subject to prior consultation with the other Party; or
	 	 	 	 
	 	 	(v)	any
    intended assignee of the rights and interests of a Party under this Agreement or to a person intending to acquire an interest
    in a Party to this Agreement as long as the intended assignee or acquirer in turn is required by that Party to treat the Confidential
    Information as confidential in favor of the other Party on terms substantially the same as those set out in this Section 12.1.

 

    	 	 	 

    	 	19	 

    

 

	12.2	Irreparable
                                         Harm

 

Each
Party acknowledges and confirms that the actual or threatened breach of a Party’s obligations of confidentiality set out
herein shall cause the non-breaching Party immediate and irreparable harm and such non-breaching Party shall be entitled to seek,
subject to Section 16.10, immediate injunctive relief, without need to post bond, restraining the breaching Party from such breach
or threatened breach, in addition to any other remedies available to it in law or equity.

 

	12.3	Public
                                         Statements

 

No
public announcement or statement concerning the execution and delivery of this Agreement and the transactions contemplated by
this Agreement shall be made by a Party, its Affiliates or their respective directors, officers, employees or shareholders without
the prior written consent of the other Party (in each such case such consent not to be unreasonably withheld or delayed) unless
such disclosure is required by Applicable Law, a recognized stock exchange or a Governmental Authority and, in such circumstances,
subject to prior consultation with the other Party. Notwithstanding the foregoing, if at any time during the Term there is a mandatory
or voluntary recall of a Product or a “serious adverse reaction” (as that term is defined in the Regulations) by any
person to the Product, the Parties shall consult with one another prior to releasing any public announcement or statement concerning
the foregoing.

 

Article
XIII

INDEMNIFICATION

 

	13.1	Mutual
                                         Indemnification

 

	 	(a)	Subject
    in all cases to the limitations of liability expressly set out in this Agreement, each Party (each, an “Indemnifying
    Party”) agrees to indemnify, defend or hold harmless the other Party, its Affiliates and each of their respective
    officers, directors, employees, agents, representatives, successors, and assigns (each, an “Indemnified Party”)
    from any and all Losses arising from or in connection with any of the following:
	 	 	 	 
	 	 	(i)	any
    material inaccuracy of any representation or warranty given by the Indemnifying Party in this Agreement or any agreement,
    instrument or document executed in connection with this Agreement;
	 	 	 	 
	 	 	(ii)	any
    material breach by the Indemnifying Party of any covenant or provision of this Agreement, including any breach by the Indemnifying
    Party that was caused by or contributed to by any act or omission of its Affiliates, and their respective officers, directors,
    employees, agents, representatives, successors, and assigns; and
	 	 	 	 
	 	 	(iii)	the
    failure of the Indemnifying Party, its Affiliates, and their respective officers, directors, employees, agents, representatives,
    successors, and assigns to comply with Applicable Law in the performance of its obligations hereunder.
	 	 	 	 
	 	(b)	In
    addition, subject in all cases to the limitations of liability expressly set out in this Agreement, the Genecor Indemnifying
    Party agrees to indemnify, defend or hold harmless the Frelii Indemnified Party from any and all Losses arising from or in
    connection with (i) any defect or deficiency related to any combination of the Products with a product of Genecor, including
    any Losses arising from or in connection with any adverse reaction experienced by any person to a Genecor product, and (ii)
    the acts or omissions of any Subcontractor.

 

    	 	 	 

    	 	20	 

    

 

	13.2	Conditions
                                         to Indemnity.

 

Each
Party’s agreement to indemnify and hold the other harmless is conditioned upon the Indemnified Party: (a) providing written
notice to the Indemnifying Party of any claim, demand or action arising out of the indemnified activities within 30 calendar days
after the Indemnified Party has knowledge of such claim, demand or action; (b) permitting the Indemnifying Party to assume full
responsibility to investigate, prepare for and defend against any such claim or demand; (c) assisting the Indemnifying Party,
at the Indemnifying Party’s reasonable expense, in the investigation of, preparation of and defense of any such claim or
demand; and (d) the Indemnifying Party not compromising or settling such claim or demand without the Indemnified Party’s
prior written consent, unless such settlement includes as an unconditional term thereof the giving by the claimant or plaintiff
to such Indemnified Party a complete release from all liability in respect of such claim or litigation; provided, however,
that, if the Party entitled to indemnification fails to promptly notify the Indemnifying Party pursuant to the foregoing clause
(a), the Indemnifying Party shall only be relieved of its indemnification obligation to the extent it is prejudiced by such failure
and provided further that the Indemnified Party is not obligated to notify the Indemnifying Party of claims, demands and/or actions
made directly against the Indemnifying Party only. Notwithstanding the foregoing, if in the reasonable judgment of the Indemnified
Party, such suit or claim involves an issue or matter which could have a materially adverse effect on the business, operations
or assets of the Indemnified Party, the Indemnified Party may waive its rights to indemnity under this Agreement and control the
defense or settlement thereof, but in no event shall any such waiver be construed as a waiver of any indemnification rights such
Indemnified Party may have at law or in equity.

 

	13.3	Insurance.

 

Each
Party shall maintain, at its own cost, comprehensive product liability insurance and general commercial liability insurance and
Genecor shall maintain manufacturer’s errors and omissions insurance, each in an amount of not less than $1,000,000. Such
insurance shall be with a reputable insurance company and where reasonably possible (taking into account the availability of such
insurance) shall be maintained for not less than six years following the expiry or termination of this Agreement.

 

Article
XIV

CHANGE IN LAW

 

	14.1	Change
                                         in Law

 

	 	(a)	The
    Parties acknowledge and confirm that the business of marketing, advertising, promoting, sublicensing or soliciting for sale
    of Products is subject to extensive regulation and Applicable Law. The Parties have attempted to structure their relationship
    pursuant to this Agreement in compliance with all Applicable Law. However, if, at any time during the Term, (i) there is discovered
    to be a compliance failure by a Party with respect to then-current Applicable Law, or (ii) there is any change in any Applicable
    Law with which a Party is required to comply and, as a result of such compliance or in order to rectify non-compliance, as
    the case may be, such Party is no longer able to comply with one or more provisions of this Agreement (each such change, a
    “Change of Law”) the affected Party shall promptly notify (a “Change of Law Notice”)
    in writing the non-affected Party of the Change of Law and any such notice shall contain a description of the Change of Law
    (with supporting documentation), the exact obligations under this Agreement which the affected Party is delayed or prevented
    from performing as a result of such Change of Law (the “Affected Obligations”).

 

    	 	 	 

    	 	21	 

    

 

	 	(b)	Upon
    delivery of a Change of Law Notice, the Designated Representatives of each Party will meet within 10 calendar days and, in
    good faith, use their commercially reasonable efforts to agree on amendments to this Agreement necessary and appropriate to
    take account of the Change of Law, so that this Agreement may continue in force (a “Change of Law Amendment”).
    All Change of Law Amendments shall be agreed to by the Designated Representatives of the Parties no later than 30 calendar
    days from the date of the Change of Law Notice, or such later date as the Designated Representatives of the Parties may mutually
    agree in writing (the “Change Period”). Without limiting the generality of the foregoing, where a Change
    of Law Amendment would result in additional costs being incurred disproportionately by one Party, the Parties shall negotiate
    in good faith to ensure that the contractual arrangements remain beneficial to both Parties.
	 	 	 
	 	(c)	During
    the Change Period the obligation of the affected Party to perform the Affected Obligations shall be suspended and the affected
    Party shall not suffer or incur any liability to the non-affected Party or other person in connection with its delayed or
    non-performance of the Affected Obligations, provided that the affected Party has used and continues to use its commercially
    reasonable good faith efforts to minimize the impact of its delay or non-performance of the Affected Obligations, including
    cooperating and collaborating with the non-affected Party to impose interim procedures or workarounds to minimize the impact
    of its delay or non-performance of the Affected Obligations.

 

Article
XV

TERM AND TERMINATION

 

	15.1	Term.

 

This
Agreement shall be for an initial term (the “Initial
Term”) of 50 years commencing on the Effective Date. Following the expiry of the Initial
Term, this Agreement shall automatically be renewed, for additional terms (the “Additional Terms”)
of 5 years each, (the Initial Term and all Additional Terms being hereinafter collectively called the “Term”)
unless either Party gives the other party notice, at least 60 days in advance of the next renewal date, of such Party’s
intent to terminate this Agreement effective as of such renewal date.

 

	15.2	Termination.

 

Each
of Genecor or Frelii may terminate this Agreement immediately upon written notice to Genecor or Frelii as the case may be upon
the occurrence of an Event of Default with respect to the other party and vice versa which is not cured within any applicable
curative period as set out in section 15.3 hereof.

 

    	 	 	 

    	 	22	 

    

 

	15.3	Event
                                         of Default

 

The
occurrence of any one or more of the following events shall constitute an “Event of Default” hereunder:

 

	 	(a)	a
    Party is in breach of any payment obligation of this Agreement or any other agreement, document or instrument executed and
    delivered in connection therewith, and such breach is not cured within 30 calendar days of written notice from the non-defaulting
    Party to the defaulting Party;
	 	 	 
	 	(b)	a
    Party is in breach of any provision not relating to a payment obligation of this Agreement or any other agreement, document
    or instrument executed and delivered in connection therewith, and such breach is not cured within 60 calendar days of written
    notice from the non-defaulting Party to the defaulting Party;
	 	 	 
	 	(c)	a
    Party commits an act of fraud or is convicted of committing an indictable criminal offense, as determined by a court of competent
    jurisdiction;
	 	 	 
	 	(d)	a
    Party assigns or attempts to assign or transfers or attempts to transfer, by operation of law or otherwise, including by way
    of merger or amalgamation, this Agreement or any rights hereunder, other than in accordance with the provisions of this Agreement;
	 	 	 
	 	(e)	the
    commencement of any Bankruptcy Proceeding in respect of a Party and such Bankruptcy Proceeding is not abandoned within 90
    calendar days of written notice from the non-defaulting Party;
	 	 	 
	 	(f)	in
    the case of Genecor, any violation of Sections 3.3(b) or 3.7; and
	 	 	 
	 	(g)	a
    Party commences dissolution, liquidation or winding-up proceedings and such proceedings are not abandoned within 30 calendar
    days of written notice from the non-defaulting Party.

 

	15.4	Effect
                                         of Termination

 

	 	(a)	In
    the event 15.3(e) (g), the following shall apply:

 

	 	(i)	In
    the case of Frelii, Gencor shall immediately secure permanent ownership rights of the products, and technology, without limitation.
    For further clarity, Frelii shall immediately transfer ownership of all Intellectual Property related to Navii to Gencor.
	 	 	 
	 	(ii)	In
    the case of Gencor, Frelii shall immediately secure all rights for the contracts in force, and all non-secured assets.

 

	 	(b)	Upon
    the termination or expiration of this Agreement, each Party shall promptly return to the other Party or destroy all Confidential
    Information of the other Party in the possession or control of the Party or its Affiliates and their respective officers,
    directors, employees, agents, Affiliates, representatives, successors or assigns, except such Confidential Information retained
    pursuant to applicable document retention policies and electronic backup systems.
	 	 	 
	 	(c)	All
    terms and conditions set forth herein that should by their nature survive termination (including, but not limited to, Sections
    3.4, 3.6, 3.9, 4.3, 4.4, 4.6, 4.7, 5.1, 5.2, 7.1(a), 7.4-7.6, Article VIII, Articles X-XIII, Section 15.4, and Article XVI),
    and shall continue in full force and effect after any expiration or termination of this Agreement or any applicable Order.

 

    	 	 	 

    	 	23	 

    

 

Article
XVI

MISCELLANEOUS

 

	16.1	Inurement.

 

This
Agreement shall inure to the benefit of and be binding upon the Parties and their respective successors, legal representatives
and permitted assigns.

 

	16.2	Assignment
                                         and Change of Control.

 

	 	(a)	Except
    as otherwise provided in Section 16.2(b) hereof, neither Party may assign this Agreement or its rights hereunder without the
    prior written consent of the other Party, which consent may not be unreasonably withheld or delayed; provided, however, that
    Frelii may assign this Agreement and its rights and obligations hereunder, without the need to obtain consent, to an Affiliate
    Party or to a successor in interest to substantially all of the business of Frelii to which the Agreement relates.
	 	 	 
	 	(b)	Notwithstanding
    anything herein to the contrary, Genecor shall not enter into any Change of Control, except with the prior written on consent
    of Frelii. Any breach by Genecor of its obligations under the preceding sentence shall constitute an Event of Default, which
    shall entitle Frelii to terminate this Agreement immediately upon notice to Genecor.

 

	16.3	Compliance
                                         with Anti-Bribery Laws.

 

Genecor
represents and warrants that it understands the US Foreign Corrupt Practices Act, the UK Bribery Act, the Council of Europe Criminal
Law Convention on Corruption, the Council of Europe Civil Law Convention on Corruption, the European Union Convention Against
Corruption Involving Officials, and the OECD Convention on Combating Bribery of Foreign Public Officials in International Business
Transactions (collectively the “Anticorruption Laws”), and their applicability to conduct in the Territory. Genecor
agrees not to cause Frelii to breach the Anticorruption Laws, and agrees to comply with the Anticorruption Laws as if they were
applicable to Genecor. Genecor agrees to accurately record in its books and records any and all expenses related to Frelii business.
Genecor represents that none of the officers, directors, shareholders, or beneficial owners of Genecor are government officials.
All payments to Genecor by Frelii will be [by check or wire transfer and will be made payable to Genecor as provided for in this
Agreement.] Genecor agrees to grant Frelii reasonable access to Genecor’s books and records and the right to audit them
on a periodic basis, including if Frelii has reason to believe Genecor may have violated any of the Anticorruption Laws. The terms
of this Agreement may be disclosed to the relevant government authorities, if deemed appropriate by Frelii in its sole discretion.
Genecor agrees to disclose in advance to Frelii any future affiliation between Genecor and a government official. Genecor agrees
to provide Frelii with periodic certifications, in a form and manner acceptable to Frelii, of compliance with the Anticorruption
Laws as if Genecor were subject to those laws. Frelii may terminate this Agreement immediately upon notice to Genecor if Frelii
has reason to believe that Genecor has breached any of the Anticorruption Laws. Genecor agrees to comply with United States and
all applicable export laws, orders and regulations and obtain all necessary governmental permits, licenses and clearances.

 

    	 	 	 

    	 	24	 

    

 

	16.4	Setoff
                                         Permitted.

 

Notwithstanding
anything herein to the contrary, and without prejudice to any other right or remedy it has or may have, Frelii may, at its option
and without notice to Genecor, set off or recoup any liability Genecor owes to Frelii against any amounts payable to Genecor,
whether the liability arises under this Agreement or otherwise.

 

	16.5	Notices.

 

All
notices or other communications that are required or permitted hereunder will be in writing and delivered personally with acknowledgement
of receipt, sent by electronic mail (provided receipt is acknowledged), facsimile (and promptly confirmed by personal delivery,
registered or certified mail or overnight courier as provided herein), sent by nationally-recognized overnight courier or sent
by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:

 

If
to Frelii, to:

 

Frelii
Inc.

722
W Shephard Lane, #102

Farmington,
UT 84025

USA

 

Attention:
          Ian Jenkins, CEO

 

If
to Genecor, to:

 

1180
Aerowood Dr, Ste 201

Mississauga,
ON L4W 1Y5

Canada

 

or
to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance
herewith. Any such communication will be deemed to have been given: (a) when delivered, if personally delivered; (b) on the business
day (on the receiving end) after dispatch, if sent by nationally-recognized overnight courier (third business day if sent internationally);
(c) on the third business day following the date of mailing, if sent by mail; and (d) on the first business day (on the receiving
end) after being sent by facsimile or by if sent by electronic. It is understood and agreed that this Section 16.3 is not intended
to govern the day-to-day business communications necessary between the Parties in performing their duties, in due course, under
the terms of this Agreement.

 

	16.6	Independent
                                         Contactors

 

The
Parties are independent contractors. There is no relationship of partnership, joint venture, employment, franchise, or agency
between the Parties. Within this document, any terms used to describe the Parties or the nature of their activities is purely
for convenience, and not of legal significance. Neither Party shall have any power to bind the other Party or incur obligations
on the other Party’s behalf without the other Party’s prior written consent. Neither Party shall represent itself
in any way that implies that it is an agent, employee, joint venture, partner or Affiliate of the other Party. If any provision
of this Agreement is deemed to create a franchise relationship between the Parties, then Frelii may immediately terminate this
Agreement.

 

    	 	 	 

    	 	25	 

    

 

	16.7	Non-Competition

 

During
the Term and for five (5) years after the termination of this Agreement for any reason, Genecor will not directly or indirectly,
without the prior written consent of the Frelii, engage, invest in, manage, operate, finance, advise, render services to, or be
contracted by any person or entity in the Territory engaged in business involving or related to the Field; provided, however,
that Genecor may acquire or otherwise own less than 3% of the outstanding capital stock of a company that is listed on any national
securities exchange.

 

	16.8	Non-Solicitation.

 

During
the Term and for five (5) years after the termination of this Agreement for any reason, Genecor shall not, directly or indirectly
through another person or entity, (i) induce or attempt to induce any employee of Frelii or any of its Affiliates to leave the
employ of Frelii or its Affiliates, or in any way interfere with the relationship between Frelii or its Affiliates and any employee
thereof, (ii) be involved in hiring or hire or employ any person who is or was an employee of Frelii or its Affiliates during
the six month period prior to the time of such hire, or (iii) call on, solicit or service any customer, supplier, licensee, licensor,
franchisee or other business relation of Frelii or its Affiliates with whom Genecor did business or had contact during the Term
for any business that competes with Frelii or any of its Affiliates, or in any way interfere with the relationship between any
such customer, supplier, licensee, licensor, franchisee or business relation and Frelii or its Affiliates (including inducing
such person or entity to cease doing business with Frelii or its Affiliates or making any negative statements or communications
about Frelii or any of its Affiliates), other than as expressly instructed by Frelii during the Term, or in order to carry out
Genecor’s duties to Frelii pursuant to this Agreement.

 

	16.9	Severability.

 

Each
of the provisions contained in this Agreement are distinct and severable and a declaration of invalidity or unenforceability of
any such provision or part thereof by a court of competent jurisdiction shall not affect the validity or enforceability of any
other provision hereof.

 

	16.10	Governing
                                         Law.

 

This
Agreement will be governed by and construed in accordance with the law of the State of Utah, U.S.A.

 

	16.11	Dispute
                                         Resolution.

 

In
the event of any dispute, controversy, or claim arising out of or relating to this Agreement, or the breach, termination or invalidity
thereof, the Parties shall first, by mutual consent, select an independent mediator to mediate such dispute, controversy or claim,
provided that such mediation will not be binding upon any of the Parties. In the event that the Parties are unsuccessful in resolving
the dispute through mediation, a Party (the “Initiating Party”) may submit the dispute for binding arbitration
in Salt Lake City, Utah, pursuant to an Expedited Arbitration Proceeding as follows. “Expedited Arbitration Proceeding”
means a binding arbitration conducted under the expedited procedures provisions of the Commercial Arbitration Rules of the American
Arbitration Association (“AAA”) then prevailing in the area.

 

    	 	 	 

    	 	26	 

    

 

	 	(a)	The
    Initiating Party shall submit the dispute to arbitration by delivering notice (each such notice being herein called an “Arbitration
    Notice”) of its desire to the other Party (the “Responding Party”), which notice shall describe
    the dispute in question, indicate the provision(s) of this Agreement under which such dispute arose and appoint, and set forth,
    the name and address of, the person who will act as Arbitrator on the Initiating Party’s behalf in connection with the
    dispute in question.
	 	 	 
	 	(b)	The
    Responding Party, within 10 business days after its receipt of the Arbitration Notice, shall give notice to the Initiating
    Party, which notice shall appoint, and set forth the name and address of, a second Arbitrator with respect to the dispute
    in question (it being agreed that if (x) the Responding Party fails to appoint a second Arbitrator within such 10-business
    day period and (y) such failure continues for two business days after the Responding Party receives a notice of such failure
    from the Initiating Party, then the first Arbitrator may appoint such second Arbitrator).
	 	 	 
	 	(c)	If,
    within 20 business days (the “Discussion Period”) following the appointment of the second Arbitrator (however
    such second Arbitrator is appointed), the two appointed Arbitrators are unable to agree with respect to the issue to be determined,
    then the two Arbitrators shall, within five business days following the end of the Discussion Period, appoint, by written
    instrument delivered to both the Initiating Party and the Responding Party, a third Arbitrator with respect to the dispute
    in question (it being agreed that if the two Arbitrators fail to appoint a third Arbitrator within the aforesaid five-business
    day period, then either the Initiating Party or the Responding Party may apply to the AAA, or if the AAA refuses or fails
    to act, then to a court of competent jurisdiction in the State of Utah, for the appointment of such third Arbitrator) and
    the third Arbitrator alone shall be instructed to render a decision within eight business days of such appointment.
	 	 	 
	 	(d)	Frelii
    and Genecor shall each have the right to appear and be represented by counsel before the Arbitrators and to submit such data
    and memoranda in support of their respective positions in the matter in dispute as may be reasonably necessary or appropriate
    in the circumstances.
	 	 	 
	 	(e)	Each
    Arbitrator appointed under this 16.11 (whether by Frelii, Genecor or any other person(s), organization or court) shall not
    then be employed by Frelii, Genecor or any Affiliate of Frelii or Genecor, and, in all other respects, shall be impartial.
    In addition, each Arbitrator shall have at least ten years’ of relevant experience in the areas of software licensing.
	 	 	 
	 	(f)	The
    arbitration shall be conducted as an Expedited Arbitration Proceeding. Any determination or award in such arbitration shall
    (i) be in writing, (ii) be final and conclusive on the Parties (and counterpart copies thereof shall be delivered to each
    of the Parties), and (iii) not add to, subtract from or otherwise modify the provisions of this Agreement. Judgment upon any
    such determination or award may be entered in any court having jurisdiction thereof.

 

	16.12	Entire
                                         Agreement; Modifications.

 

This
Agreement sets forth and constitutes the entire agreement and understanding between the Parties with respect to the subject matter
hereof and supersedes all prior agreements, understanding, promises and representations, whether written or oral. Each Party confirms
that it is not relying on any representations or warranties of the other Party except as specifically set forth herein. No amendment,
modification, release or discharge will be binding upon the Parties unless in writing and duly executed by authorized representatives
of both Parties.

 

    	 	 	 

    	 	27	 

    

 

	16.13	Waiver.

 

Any
term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such
waiver will be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term
or condition. Any such waiver will not be deemed a waiver of any other right or breach hereunder.

 

	16.14	No
                                         Third Party Beneficiaries.

 

The
representations, warranties, covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto
and their successors and permitted assigns, and they will not be construed as conferring any rights on any other parties.

 

	16.15	Further
                                         Assurances.

 

Each
Party will duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to
be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may
be necessary to carry out the provisions and purposes of this Agreement.

 

	16.16	Counterparts.

 

This
Agreement may be executed in any number of counterparts and by the Parties on separate counterparts, each of which is an original
but all of which together constitute one and the same instrument.

 

    	 	 	 

    	 	28	 

    

 

IN
WITNESS WHEREOF, the Parties hereto have caused this Collaboration Agreement to be executed on the date first above written.

 

	 	FRELII
    INC.
	 	 	 
	 	Per:	 
	 	Name:	Ian
    Jenkins
	 	Title:	CEO
	 	 	 
	 	GENECOR
    AI INC.
	 	 	 
	 	Per:	 
	 	Name:	Tejas
    Shah
	 	Title:	Director

 

    	 	 	 

    	 

    

 

EXHIBIT
A

 

PRODUCT
DESCRIPTION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]